Personalized Hemodynamic Resuscitation Targeting Capillary Refill Time in Early Septic Shock — The ANDROMEDA-SHOCK-2 Randomized Clinical Trial
JAMA · October 2025 · n = 1,501 patients · 86 ICUs · 19 countries
A randomized, controlled trial conducted across the Americas, Asia, and Europe between March 2022 and April 2025. Patients with early septic shock were allocated to resuscitation guided by capillary refill time (CRT ≤ 3 seconds as target) versus usual care based on current guidelines.
The primary outcome was a hierarchical composite of 28-day mortality, duration of vital support, and hospital length of stay — an analytical method that captures gradations of clinical benefit that traditional binary endpoints miss.